Embodiments described herein relate generally to compounds comprising allyl lactide residues. One aspect described herein relates generally to a compound or a pharmaceutically acceptable salt thereof, comprising allyl lactide residues and lactide residues, wherein the compound or pharmaceutically acceptable salt thereof is substantially free of valerolactone residues. Another aspect relates to a method of incorporating a drug into a compound, comprising: (i) providing a compound or a pharmaceutically acceptable salt thereof, comprising allyl lactide residues and lactide residues, wherein the compound or pharmaceutically acceptable salt thereof is substantially free of valerolactone residues; (ii) incubating the compound and a drug in the presence of a solvent for an incubation period to form a drug-loaded compound; and (iii) separating the drug-loaded compound from the solvent.

Methods of making and using nanoparticle pharmaceutical compositions comprising histidine-lysine copolymers are provided. The solutions spontaneously form nanoparticles when mixed with nucleic acids such as siRNA. Methods are provided where the pH of the nucleic acid solution is controlled prior to mixing leading to a reduction in nanoparticle diameter to a desirable range, typically 100-150 nm, and Polydispersity Index (PDI), both of which improve transport into target cells to improve the efficacy of gene silencing.

The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Network materials which exhibit both shear thinning and self-healing properties are disclosed. The networks contain particles and gel-forming compounds. The networks are useful for a variety of biomedical uses, including drug delivery.

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

Methods for preparing particles and related compositions are provided. In some embodiments, the particles include at least one polynucleotide (e.g., mRNA), and in certain embodiments, the particles may include at least one ionizable molecule (e.g., a lipid). A method for preparing a suspension including the particles may comprise one or more filtration steps. In some such embodiments, prior to or during filtration, one or more properties of the particles (e.g., surface charge) and/or one or more properties of the suspension (e.g., pH) may be altered. In some embodiments, altering one or more properties of the particles and/or suspension may improve yield, improve a characteristic of the resulting composition, and/or prevent or reduce certain problems, such as fouling during the filtration process.

A product for preventing and treating external genitalia infection and/or flat warts is provided, wherein the product comprises a chloroquine nanosphere. The chloroquine nanosphere comprises a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative. A mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier during preparation ranges from 1:3 to 1:5. A loading rate of the chloroquine or the chloroquine derivative in the prepared chloroquine nanosphere ranges from 3.0% to 21.6%. The water-soluble nanosphere carrier is water-soluble chitosan; a deacetylation degree of the water-soluble chitosan ranges from 80% to 95%, and a viscosity-average molecular weight thereof ranges from 3000 to 5000 g/mol. The chloroquine derivative is selected from one or more of hydroxychloroquine, chloroquine phosphate or chloroquine sulfate.

α-Bi.sub.2O.sub.3 NPs exhibit not only potent broad-spectrum antibacterial activity of killing both Gram-negative (MIC=0.75 μg/mL vs. P. aeruginosa) and Gram-positive (MIC=2.5 μg/mL vs. S. aureus) bacteria, but they are also effective against Ag-resistant and carbapenem-resistant bacteria (MICs=1.0 μg/mL and 1.25 μg/mL, respectively), and they are able to sensitize bacteria towards meropenem (mero), acting synergistically and thus allowing for its continued use with smaller therapeutic doses (fractional inhibitory concentration=0.45). Importantly, unlike other technologies that have been considered as effective metal antimicrobials, α-Bi.sub.2O.sub.3 NPs do not contribute to the generation of antimicrobial resistant phenotypes with no resistance observed after 30 passages. The Bi-based materials represent a critical tool against multidrug resistant bacteria.

The present disclosure relates to a nanoparticle compound, including: a hydrophilic polymer, a linker, and a drug, wherein the drug is linked to the hydrophilic polymer by the linker, wherein the drug is mithramycin A or a derivative thereof, and wherein the linker is boronic acid or a boronic acid derivative. For example, the present disclosure includes one or more nanoparticles including one or more conjugates, and methods of using the nanoparticles for drug delivery, and treating a disease such as Ewing sarcoma or osteosarcoma.

The present disclosure relates to a nanoparticle compound, including: a hydrophilic polymer, a linker, and a drug, wherein the drug is linked to the hydrophilic polymer by the linker, wherein the drug is mithramycin A or a derivative thereof, and wherein the linker is boronic acid or a boronic acid derivative. For example, the present disclosure includes one or more nanoparticles including one or more conjugates, and methods of using the nanoparticles for drug delivery, and treating a disease such as Ewing sarcoma or osteosarcoma.